Aditum Bio

Aditum Bio describes itself as a biotech venture capital firm built to translate scientific discoveries into new medicines. Rather than backing companies across the full life of drug development, it says it concentrates specifically on the translation phase, identifying and advancing drug candidates into the clinic. The firm was launched by a former chief executive of Novartis, Joe Jimenez, together with Dr Mark Fishman, formerly president of the Novartis Institutes for BioMedical Research; the site presents their scientific and operating experience as the basis for how candidates are selected. Aditum Bio says its model allows rapid company formation, planning and execution, with the aim of improving outcomes for patients and generating returns for its investors. The site does not name specific portfolio companies or say where the firm is based.